# ELIMINATE UNPREDICTABILITY IN SITE SELECTION

WCG Site ID and Intelligence Delivers the Best Investigators and Optimizes Enrollment, Leading to Significant Savings





ou need access to real-time data on investigator performance, and you need expert insights to interpret that data.

Part of WCG's feasibility solution, Site ID & Intelligence uses historical performance data from thousands of global clinical trials, investigators and institutions to find the precise match for a study's therapeutic approach and protocol.

Leverage WCG's data on 95% of all industry-sponsored research as well as demographic and performance metrics for more than 140,000 investigators worldwide. This proprietary data allows us to give each client a specific, hand-tailored list of sites most likely to be high enrollers for their upcoming study. It also allows us to provide insights into the enrollment and competitive landscape for their primary indication.

By reducing unpredictability in site performance, you end up with greater reliability and less risk. That translates into faster time to your next key decision point, improved ROI and better insight into study planning timelines and targets.

We demonstrated this with an analysis of an actual major depressive disorder trial. By selecting verified top-performing investigators through WCG, the sponsor could have cut enrollment by six months and saved at least \$400,000 in fully loaded costs.

#### THE ANALYSIS

To assess how WCG enhances study enrollment, we conducted a retrospective analysis of a completed phase 2 trial for major depressive disorder. The U.S.-based trial required 250 patients; the actual study enrollment was 0.76 patients per site per month (PPSPM). Enrollment took 13.24 months to complete.

Using WCG data, we identified which of their 25 investigators ranked in the top two quartiles of historical performance in major depressive disorder studies. Had the sponsor used the top 18 sites from this analysis, enrollment was projected to be 1.32 PPSPM over the 13-month enrollment period.

With insights from WCG analysis, the sponsor could have reduced the total number of sites needed to meet enrollment targets from 25 to 18 (a 28% reduction), based on the expected

optimized enrollment rates of the top-quartile investigators. Using a conservative estimate of \$50,000 per site for activation costs, the sponsor would have saved \$400,000, a figure that does not factor in the savings accrued by a shorter enrollment period. Fewer sites also mean less variation, which improves study reliability.

WHAT WAS DIFFERENT


WCG's analysis identified sites ranked in the top two quartiles. In the actual investigator cohort, 28% of the sites ranked in the bottom two quartiles. Based on historical data, those sites are considered lower performing compared to their peers.

Although most investigators in this study were top performers, the sponsor still had room for improvement. Eliminating the low-performing sites would have resulted in better-quality sites. Better-quality sites typically have faster, more costefficient enrollment.


## OPTIMIZE SITE SELECTION WITH PRECISE DATA

The implications are clear: By working with only high-performing sites, sponsors can substantially improve their chances of reaching critical enrollment milestones, leading to significant savings.

#### **Before WCG Site ID & Intelligence**



#### After WCG Site ID & Intelligence



#### **WANT TO LEARN MORE?**

WCG Site ID & Intelligence provides more relevant metrics about more investigators than any other site-identification tool available in the industry due to the breadth and depth of data that is aggregated, curated and validated. Using this information, WCG runs a series of proprietary algorithms that yield a subset of investigators representing the ideal investigator profile defined for the unique study. The analytics tool force-ranks the subset of identified investigators in order of predictive performance: Quartile 1, 2, 3 or 4.

### SUCCESSFUL ENROLLMENT REQUIRES SELECTION OF PRODUCTIVE INVESTIGATOR / SITES





609.945.0101

wcgclinical.com